



# ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.

Phone : +91 7226995613/14/15 | +91 79 4002 3839

Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.

E-mail : [ishitadrugs@gmail.com](mailto:ishitadrugs@gmail.com) | [info@ishitadrugs.com](mailto:info@ishitadrugs.com) | URL : [www.ishitadrugs.com](http://www.ishitadrugs.com)

Date: 09<sup>th</sup> November, 2020

To,  
The Company Section  
The Bombay Stock Exchange  
Phiroz Jijibhoy Towers  
Dalal Street, Bombay- 400 001

**Security Code: 524400**

Dear Sir,

**Sub: Outcome of Board Meeting held on 09<sup>th</sup> November, 2020 pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015.**

This is to inform you that the Board of directors of the Company at its meeting held today on Monday, the 09<sup>th</sup> Day of November, 2020 have

1. Approved the Unaudited Financial Results of the Company along with the Limited Review Report for the quarter and half-year ended on 30<sup>th</sup> September, 2020 pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015.

Hope the enclosed papers are in accordance with requirements. Please take the same on your records and do the needful.

Thanking You.

For, Ishita Drugs & Industries Ltd.

Vijay Shah

Company Secretary and Compliance Officer



*"Our basic drugs in the service of humanity worldwide"*

CIN No. L24231GJ1992PLC017054

D & B D-U-N-S Number - 65-018-0359



Date: 09/11/2020

To,  
The Board of Directors,  
Ishita Drugs & Industries Limited,  
Ahmedabad.

**LIMITED REVIEW REPORT**

We have reviewed the accompanying of unaudited financial results of **ISHITA DRUGS AND INDUSTRIES LIMITED** for the period **01 July 2020 to 30 Sep 2020** (The Statement) being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim financial information performed by the Independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with Indian accounting standards prescribe under section 133 of companies Act, 2013 read with relevant rules issued there under and another recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI ( Listing Of Obligation and Disclosure Requirements) Regulation, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of  
**JAYMIN SHAH & ASSOCIATES**



CA Mayank Sancheti  
M No. 170863  
Date: 09/11/2020  
Place: Ahmedabad  
UDIN: 20170863AAAADU1251

Corp. Office : 410-411, Lilamani Corporate Heights, Opp. Ramapir Brts Bus Stand, Nr. Ozone Aangan, New Wadaj, Ahmedabad - 380013, Gujarat  
Branch Office : 504, Palladium Business Hub, Above Pantaloons, Opp. 4D Mall - PVR Cinema, Visat-Gandhinagar Highway, Ahmedabad-382424

☐ CA Mayank Sancheti +91 8000331632 / 7048685472  
Deepak Surana +91 9429913706  
● GSTIN : 24AAOFJ1119R1ZY

✉ camayanksancheti@gmail.com  
dpaksurana4u@gmail.com

ISHITA DRUGS AND INDUSTRIES LIMITED

CIN: L24231GJ1992PLCO17054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad - 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613/14/15

Unaudited Financial Results for the Quarter and Half year Ended September 30, 2020

Particulars	Amount in Lacs except Per Share data					
	Quarter Ended			Half Year Ended		Year Ended
	3 Months Ended Un-audited 30-Sep-20	3 Months Ended Un-audited 30-Jun-20	3 Months Ended Un-audited 30-Sep-19	6 Months Ended Un-audited 30-Sep-20	6 Months Ended Un-audited 30-Sep-19	12 Months Ended Audited 31-Mar-20
<b>1 INCOME</b>						
Revenue from Operations	379,629	230,401	360,766	610,030	746,830	1481,812
Other Income	3,683	0,380	2,419	4,063	5,317	17,646
<b>Total Income</b>	<b>383,312</b>	<b>230,781</b>	<b>363,185</b>	<b>614,093</b>	<b>752,147</b>	<b>1499,458</b>
<b>2 EXPENSES</b>						
(a) Cost of Material Consumed	303,691	153,916	277,961	457,607	575,695	1135,527
(b) Purchase of Stock-in-Trade	0,000	1,469	0,000	1,469	2,903	9,253
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-9,285	-2,597	2,058	-11,882	7,955	-0,265
(d) Employee Benefit Expense	25,902	25,611	26,528	51,513	53,263	109,795
(e) Finance Cost	0,618	0,567	1,084	1,185	1,969	3,470
(f) Depreciation, Depletion and Amortisation Expense	4,436	4,437	3,580	8,873	7,795	17,747
(g) Other Expense	38,814	35,316	35,483	74,130	70,159	152,587
<b>Total Other Expenses</b>	<b>38,814</b>	<b>35,316</b>	<b>35,483</b>	<b>74,130</b>	<b>70,159</b>	<b>152,587</b>
<b>Total Expenses</b>	<b>364,176</b>	<b>218,719</b>	<b>346,694</b>	<b>582,895</b>	<b>719,739</b>	<b>1428,114</b>
<b>3 Total Profit before Exceptional Items and Tax</b>	<b>19,137</b>	<b>12,061</b>	<b>16,491</b>	<b>31,198</b>	<b>32,408</b>	<b>71,344</b>
4 Exceptional Items	0,000	0,000	0,000	0,000	0,000	0,000
<b>5 Total Profit before Tax</b>	<b>19,137</b>	<b>12,061</b>	<b>16,491</b>	<b>31,198</b>	<b>32,408</b>	<b>71,344</b>
6 Tax Expense	4,000	3,000	3,794	7,000	7,510	17,500
7 Current Tax	0,000	0,000	0,000	0,000	0,000	-0,870
8 Deferred Tax	4,000	3,000	3,794	7,000	7,510	16,630
9 Total Tax Expenses	4,000	3,000	3,794	7,000	7,510	16,630
10 Net Movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0,000	0,000	0,000	0,000	0,000	0,000
<b>11 Net Profit Loss for the period from continuing operations</b>	<b>15,137</b>	<b>9,061</b>	<b>12,697</b>	<b>24,198</b>	<b>24,898</b>	<b>54,714</b>
12 Profit / (Loss) from discontinued operations before tax	0,000	0,000	0,000	0,000	0,000	0,000
13 Tax Expenses of discontinued operations	0,000	0,000	0,000	0,000	0,000	0,000
14 Net Profit / (Loss) from discontinued operations after tax	0,000	0,000	0,000	0,000	0,000	0,000

*Jaydevin Chandra*



15	Share of Profit / (Loss) of associates and joint ventures accounted for using equity method		0.000		0.000		0.000		0.000		0.000		0.000
16		<b>Total Profit / (Loss) for the period</b>	<b>15,137</b>	9,061	12,697	<b>24,198</b>	24,898	54,714					
17		Other Comprehensive Income net of Taxes	0.000	0.000	0.000	0.000	0.000	0.000					
18		<b>Total Comprehensive Income for the Period</b>	<b>15,137</b>	9,061	12,697	<b>24,198</b>	24,898	54,714					
19	<b>Total profit or loss attributable to</b>												
	Profit or loss, attributable to owners of parents		0.000	0.000	0.000	0.000	0.000	0.000					
	Total Profit or loss, attributable to non-controlling interests		0.000	0.000	0.000	0.000	0.000	0.000					
20	<b>Total comprehensive income for the period attributable to</b>												
	Comprehensive Income for the period attributable to the owners of parent non-controlling interests		0.000	0.000	0.000	0.000	0.000	0.000					
21	<b>Details of Equity Share Capital</b>												
	Paid-Up Equity Share Capital		299,030	299,030	299,030	299,030	299,030	299,030					
	Face Value of Equity Share Capital		10,000	10,000	10,000	10,000	10,000	10,000					
22	<b>Details of Debt Securities</b>												
	Paid-Up Debt Capital		0.000	0.000	0.000	0.000	0.000	0.000					
	Face Value of Debt Securities		0.000	0.000	0.000	0.000	0.000	0.000					
23	Reserves Excluding Revaluation Reserves		0.000	0.000	0.000	0.000	0.000	0.000					
24	Debt Redemption Reserve		0.000	0.000	0.000	0.000	0.000	0.000					
25	<b>Earnings Per Share</b>												
	<b>Earnings Per Share for continuing operations</b>												
	Basic Earnings / (Loss) per share from continuing operations		0.506	0.303	0.425	0.809	0.833	1.850					
	Diluted Earnings / (Loss) per share from continuing operations		0.506	0.303	0.425	0.809	0.833	1.850					
	<b>Earnings Per Share for discontinued operations</b>												
	Basic Earnings / (Loss) per share from discontinued operations		0.000	0.000	0.000	0.000	0.000	0.000					
	Diluted Earnings / (Loss) per share from discontinued operations		0.000	0.000	0.000	0.000	0.000	0.000					
	<b>Earnings per Equity Share</b>												
	Basic Earnings / (Loss) per share from continuing and discontinued operations		0.506	0.303	0.425	0.809	0.833	1.830					
	Diluted Earnings / (Loss) per share from continuing and discontinued operations		0.506	0.303	0.425	0.809	0.833	1.830					
26	Debt Equity Ratio		--	--	--	--	--	--					
27	Debt Service Coverage Ratio		--	--	--	--	--	--					
28	Interest Service Coverage Ratio		--	--	--	--	--	--					

*Josephine M. M. M.*



**NOTES**

1. The above Financial Results were reviewed by the Audit Committee and thereafter were approved and taken on record by the Board of Directors in their meeting held on November 09, 2020.
2. The Limited Review of the results has been completed by the Statutory Auditors of the Company.
3. As per Indian Accounting Standard (IndAS) "Operating Segment", the Company's business falls within a single business segment viz. "Pharmaceutical Business".
4. The financial results for the quarter and half year ended 30th September, 2020 are also Ind AS compliant. The management has exercised necessary due diligence to ensure that the financial results give a true and fair view.
5. Previous quarter's amounts have been re-grouped/re-classified, wherever considered necessary to make them comparable with those of the current quarter.
6. Results are available at Company's website [www.ishitadrugs.com](http://www.ishitadrugs.com) and also at [www.bseindia.com](http://www.bseindia.com).

For, ISHITA DRUGS AND INDUSTRIES LIMITED



*Jagdish Agrawal*

JAGDISH AGRAWAL

MANAGING DIRECTOR

DIN: 01031687

Place	Ahmedabad	
Date	9-Nov-20	

**ISHITA DRUGS AND INDUSTRIES LIMITED**

CIN: L24231GJ1992PLC017054

Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand

Ahmedabad – 382170

Website: www.ishitadrugs.com

Contact: +91 7226995613

**Statement of Assets and Liabilities**

Amount in ₹

Particulars	Half Year Ended	Previous Year Ended
	6 Months Ended	12 Months Ended
	Unaudited	Audited
	30-Sep-20	31-Mar-20
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
Property, plant and equipment	10482616	11369951
Capital work-in-progress		
Investment property		
Goodwill		
Other intangible assets		
Intangible assets under development		
Biological assets other than bearer plants		
Investments accounted for using equity method		
<b>Non-current financial assets</b>	<b>10482616</b>	<b>11369951</b>
Non-current investments	2068098	2068098
Trade receivables, non-current		
Loans, non-current		
Other non-current financial assets	506200	506200
<b>Total Non-current financial assets</b>	<b>2574298</b>	<b>2574298</b>
Deferred tax assets (net)		
Other non-current assets		
<b>Total Non-current Assets</b>	<b>13056914</b>	<b>13944249</b>
<b>2 Current assets</b>		
Inventories	8811428	5809314
<b>Current financial assets</b>		
Current investments	28601954	50866475
Trade receivables, current	24614420	13109812
Cash and cash equivalents	4354121	4017892
Bank balance other than cash and cash equivalent	5978175	5978175
Loans, current	0	0
Other current financial assets	276271	284000
<b>Total current financial assets</b>	<b>63824940</b>	<b>74256353</b>
Current tax assets (net)		
Other current assets		
<b>Total Current Assets</b>		
<b>3 Non-current assets classified as held for sale</b>		
<b>4 Regulatory deferral account debit balances and related deferred tax Assets</b>		
<b>TOTAL ASSETS</b>	<b>85693282</b>	<b>94009916</b>

*Jeydevi Agrawal*



EQUITIES AND LIABILITIES			
1	Equity		
	Equity attributable to owners of Parent		
	Equity share capital	29903000	29903000
	Other equity	42127380	39707583
	<b>Total Equity attributable to owners of Parent</b>	<b>72030380</b>	<b>69610583</b>
	Non controlling interest		
	<b>Total Equity</b>	<b>72030380</b>	<b>69610583</b>
2	Liabilities		
	Non-current liabilities		
	Non-current financial liabilities		
	Borrowing, non-current	214522	419487
	Trade payables, non-current		
	Other non-current financial liabilities		
	<b>Total Non-current financial liabilities</b>	<b>214522</b>	<b>419487</b>
	Provisions, non-current		
	Deferred tax liabilities (net)	469729	469729
	Deferred government grants, Non-current Other non-current liabilities		
	<b>Total Non-current liabilities</b>	<b>469729</b>	<b>469729</b>
	Current liabilities		
	Current financial liabilities		
	Borrowing, current	1393245	1655517
	Trade payables, current	7328238	18936050
	Other current financial liabilities	755558	993862
	<b>Total current financial liabilities</b>	<b>9477041</b>	<b>21585429</b>
	Other current liabilities		
	Provisions, current	4092997	1669022
	Current tax liabilities (Net)	-591387	255666
	Deferred government grants, Current		
	<b>Total current liabilities</b>	<b>3501610</b>	<b>1924688</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale		
4	Regulatory deferral account credit balances and related deferred tax liability		
	<b>Total Liabilities</b>		
	<b>Total Equity and Liabilities</b>	<b>85693282</b>	<b>94009916</b>

For, ISHITA DRUGS AND INDUSTRIES LIMITED



*Jagdish Agrawal*

JAGDISH AGRAWAL

MANAGING DIRECTOR

Place Ahmedabad

Date 09-Nov-20

DIN: 01031687

**ISHITA DRUGS AND INDUSTRIES LIMITED**

**CIN: L24231GJ1992PLC017054**

**Registered Office: Survey No. 179/1, Village : Vasna-Iyava, Ta. Sanand  
Ahmedabad – 382170**

**Website: www.ishitadrugs.com**

**Contact: +91 7226995613**

**UNAUDITED CASH FLOW STATEMENT**

Sr. No.	Perticulers	Unaudited Halfyear Ended 30.09.2020 Rs. In Lakhs	Audited Year Ended 31.03.2020 Rs. In Lakhs
<b>(A)</b>	<b>Cash flow from operating activities :</b>		
	<b>Profit before tax</b>	31.20	<b>71.34</b>
	<b>Add :</b> Depreciation	8.87	17.75
	Interest & Other financial charges	1.19	3.47
	Loss on sale of fixed assets	0.00	0.00
	<b>Less :</b> Interest received	2.28	4.56
	Dividend received	0.01	0.01
	Income from Investments	3.08	11.67
	<b>Operating profit before change in working capital</b>	<b>35.89</b>	<b>76.33</b>
	<b>Add :</b> Trade Debtors	(115.05)	(13.06)
	Decrease/(Increase) in Inventory	(30.02)	15.78
	Decrease/(Increase) in Loans and advances	0.08	(1.05)
	<b>Less :</b> Provision for Taxation	7.00	17.50
	Decrease/(Increase) Shore Term Provision	(24.24)	0.46
	Decrease/(Increase) Trade Creditors, Current liabilities & Provisions	124.83	(44.72)
	<b>Net cash generated from operating activities (A)</b>	<b>(216.70)</b>	<b>104.75</b>
<b>(B)</b>	<b>Cash inflow from investing activities :</b>		
	<b>Add :</b> Investment sold / (purchased)	222.65	(125.55)
	Dividend received	0.01	0.01
	Income from Investments	3.08	11.67
	<b>Less :</b> Investment in fixed assets	(0.00)	1.46
	<b>Net cash generated from investing activities (B)</b>	<b>225.74</b>	<b>-115.33</b>
<b>(C)</b>	<b>Cash flow from financial activities :</b>		
	<b>Add :</b> Interest received	2.28	4.56
	Borrowings	(6.77)	8.34
	<b>Less :</b> Interest & Other financial charges	1.19	3.47
	<b>Net cash generated from financial activities (C)</b>	<b>(5.68)</b>	<b>9.42</b>
	<b>Net Increase/(decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>3.36</b>	<b>(1.15)</b>
	Opening balance of Cash and cash equivalents	99.96	101.11
	Closing balance of Cash and cash equivalents	103.32	99.96
	<b>Net Increase/(decrease) in Cash &amp; Cash Equivalents</b>	<b>3.36</b>	<b>(1.15)</b>

Note : Figures in bracket indicate negative value  
Correctly extracted from Audited accounts of the Company

For, ISHITA DRUGS AND INDUSTRIES LIMITED

*Jagdish Agrawal*



**JAGDISH AGRAWAL**

**MANAGING DIRECTOR**

**DIN: 01031687**

Place **Ahmedabad**

Date **09-Nov-20**